Pedro Exman

1.1k total citations
21 papers, 383 citations indexed

About

Pedro Exman is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Pedro Exman has authored 21 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Pedro Exman's work include Breast Cancer Treatment Studies (7 papers), Cancer Risks and Factors (5 papers) and Advanced Breast Cancer Therapies (4 papers). Pedro Exman is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), Cancer Risks and Factors (5 papers) and Advanced Breast Cancer Therapies (4 papers). Pedro Exman collaborates with scholars based in United States, Brazil and Italy. Pedro Exman's co-authors include Sara M. Tolaney, Nancy U. Lin, Romualdo Barroso‐Sousa, Eric P. Winer, Heather A. Parsons, Joyce Lii, Inês Vaz-Luís, José Roberto Filassi, Nancy L. Keating and Rachel A. Freedman and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer and Cancer Research.

In The Last Decade

Pedro Exman

19 papers receiving 373 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pedro Exman United States 8 255 126 100 95 41 21 383
Αngeliki Andrikopoulou Greece 13 220 0.9× 89 0.7× 78 0.8× 158 1.7× 23 0.6× 41 438
Shreya Vemuri United States 6 258 1.0× 51 0.4× 162 1.6× 77 0.8× 22 0.5× 12 325
Sumitra Ananda Australia 12 224 0.9× 85 0.7× 89 0.9× 133 1.4× 16 0.4× 54 468
Melinda Laine Hsu United States 11 214 0.8× 119 0.9× 44 0.4× 160 1.7× 20 0.5× 28 422
Alberto Alvarado‐Miranda Mexico 10 188 0.7× 75 0.6× 162 1.6× 63 0.7× 24 0.6× 23 325
Xuewei Zhuang China 11 147 0.6× 64 0.5× 123 1.2× 201 2.1× 30 0.7× 26 460
Carmen Calfa United States 10 294 1.2× 140 1.1× 131 1.3× 76 0.8× 11 0.3× 40 406
Karl Verpoort Germany 7 222 0.9× 53 0.4× 98 1.0× 64 0.7× 21 0.5× 10 370
Ghieth A. Kazkaz Saudi Arabia 6 266 1.0× 113 0.9× 103 1.0× 53 0.6× 27 0.7× 8 363
Si‐Lin Koo Singapore 11 299 1.2× 165 1.3× 141 1.4× 130 1.4× 25 0.6× 28 535

Countries citing papers authored by Pedro Exman

Since Specialization
Citations

This map shows the geographic impact of Pedro Exman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedro Exman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedro Exman more than expected).

Fields of papers citing papers by Pedro Exman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pedro Exman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedro Exman. The network helps show where Pedro Exman may publish in the future.

Co-authorship network of co-authors of Pedro Exman

This figure shows the co-authorship network connecting the top 25 collaborators of Pedro Exman. A scholar is included among the top collaborators of Pedro Exman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pedro Exman. Pedro Exman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Alves, Venâncio Avancini Ferreira, et al.. (2024). Abstract PO1-17-04: Influence of regulatory agency approval of trastuzumab-deruxtecan on the diagnosis of HER2-low status at a reference cancer center in Brazil. Cancer Research. 84(9_Supplement). PO1–17. 1 indexed citations
3.
4.
Nunes, Raquel, Tal Sella, Kai Treuner, et al.. (2021). Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma. Clinical Cancer Research. 27(20). 5688–5696. 13 indexed citations
5.
Exman, Pedro & Sara M. Tolaney. (2021). HER2-positive metastatic breast cancer: a comprehensive review.. PubMed. 19(1). 40–50. 46 indexed citations
6.
Mao, Pingping, Ofir Cohen, Kailey J. Kowalski, et al.. (2020). Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clinical Cancer Research. 26(22). 5974–5989. 90 indexed citations
7.
Fréret, Thomas, Pedro Exman, Erica L. Mayer, Sarah E Little, & Katherine E. Economy. (2020). Birthweight and Chemotherapy Exposure in Women Diagnosed with Breast Cancer during Pregnancy. American Journal of Perinatology. 39(5). 554–561. 3 indexed citations
8.
Exman, Pedro, et al.. (2019). Evidence to date: talazoparib in the treatment of breast cancer. SHILAP Revista de lepidopterología. 1 indexed citations
9.
Hepner, Adriana, Pedro Exman, Laura Testa, et al.. (2019). Cancer During Pregnancy: The Oncologist Overview. World Journal of Oncology. 10(1). 28–34. 77 indexed citations
10.
Exman, Pedro, Romualdo Barroso‐Sousa, & Sara M. Tolaney. (2019). <p>Evidence to date: talazoparib in the treatment of breast cancer</p>. OncoTargets and Therapy. Volume 12. 5177–5187. 37 indexed citations
11.
Exman, Pedro, Robert M. Mallery, Nancy U. Lin, & Heather A. Parsons. (2019). Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis. npj Breast Cancer. 5(1). 46–46. 29 indexed citations
12.
Barroso‐Sousa, Romualdo, Svitlana Tyekucheva, Pedro Exman, et al.. (2019). TUMOR MUTATIONAL BURDEN (TMB) IS A POTENTIAL PREDICTOR OF RESPONSE TO IMMUNE CHECKPOINT INHIBITORS (ICI) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC). 5–5. 1 indexed citations
13.
14.
Mao, Pingping, Ofir Cohen, Kailey J. Kowalski, et al.. (2019). Abstract 314: Acquired FGF and FGFR alterations confer resistance to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer. Cancer Research. 79(13_Supplement). 314–314. 1 indexed citations
15.
Exman, Pedro, Ana C. Garrido-Castro, & Sara M. Tolaney. (2019). PD-L1 Testing in Patients with Breast Cancer: Controversies and Current Practice. Current Breast Cancer Reports. 11(4). 353–357. 1 indexed citations
16.
17.
Freedman, Rachel A., Nancy L. Keating, Nancy U. Lin, et al.. (2018). Breast cancer‐specific survival by age: Worse outcomes for the oldest patients. Cancer. 124(10). 2184–2191. 55 indexed citations
18.
Exman, Pedro & Sara M. Tolaney. (2018). Abemaciclib for the treatment of HR+/HER2- breast cancer. Expert Review of Precision Medicine and Drug Development. 3(3). 151–161. 1 indexed citations
19.
Barroso‐Sousa, Romualdo, Pedro Exman, & Sara M. Tolaney. (2018). De-Escalating Treatment in the Adjuvant Setting in Her2-Positive Breast Cancer. Future Oncology. 14(10). 937–945. 3 indexed citations
20.
Exman, Pedro, et al.. (2013). Primary Ovary Choriocarcinoma: Individual DNA Polymorphic Analysis as a Strategy to Confirm Diagnosis and Treatment. Rare Tumors. 5(2). 89–92. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Αngeliki Andrikopoulou Breakdown of academic impact, for papers by Shreya Vemuri Breakdown of academic impact, for papers by Sumitra Ananda Breakdown of academic impact, for papers by Melinda Laine Hsu Breakdown of academic impact, for papers by Alberto Alvarado‐Miranda Breakdown of academic impact, for papers by Xuewei Zhuang Breakdown of academic impact, for papers by Carmen Calfa Breakdown of academic impact, for papers by Karl Verpoort Breakdown of academic impact, for papers by Ghieth A. Kazkaz Breakdown of academic impact, for papers by Si‐Lin Koo
Rankless by CCL
2026